Video

Evan S. Dellon, MD: A Daily Diary for Eosinophilic Esophagitis

Author(s):

PROSE allows patients to report their symptoms of dysphagia in real-time.

Patients with eosinophilic esophagitis (EoE) could struggle to realize the process they are making.

However, data presented at the 2021 American College of Gastroenterology (ACG) Annual Meeting, shows using a patient-reported daily diary called the Patient Reported Outcomes for the Symptoms of Eosinophilic Esophagitis (PROSE) allowed patients to allow patients to report episodes of dysphagia in real-time, giving clinicians the ability to truly gauge the progress of the patient.

In an interview with HCPLive®, Evan S. Dellon, MD, MPH, Director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, said it is easy for patients to lose track of the kind of progress they are making, so the self-reported diary does give a better frame of reference for past performance chewing and swallowing with EoE.

In the clinical trial, 26 patients were evaluated through 5 different waves in which patients labeled their dysphagia experience as uncomfortable and/or painful episodes that typically last less than 5 minutes.

The most common impacts were food avoidance and social impacts, where the patient avoided restaurants or social gatherings or bring their own food to places.

Patients reported PROSE provided a good assessment of their dysphagia experience.

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Highlighting the Danger of SCI Progression during iTTP Remission, with Shruti Chaturvedi, MBSS, MS
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
© 2024 MJH Life Sciences

All rights reserved.